Muhammet Fatih Şahin
Research Subjects
Muhammet Fatih Şahin has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ali Erol
Bursa Specialized Training and Research Hospital, Health Sciences University, Department of Internal Medicine, Bursa, Turkey
6 shared publications - Ali Şahin
Department of Internal Medicine, Tokat State Hospital, Tokat, Turkey
2 shared publications - Aydin Dursun
Mudanya University, Vocational School, Department of Anestesia, Bursa, Türkiye
1 shared publication Aydın Dursun
VM Medical Park Hospital, Cardiology, Mudanya University, Bursa, Turkey
1 shared publication- Ayten Başak Karaakın Dinar
Department of Internal Medicine, Kestel State Hospital, Bursa, Turkey
1 shared publication - Deniz Sigirli
Department of Statistics and Business Analytics, United Arab Emirates University, Al Ain 15551, United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in BMC Endocrine Disorders
SGLT2 inhibitor use and DEXA-derived bone health in type 2 diabetes mellitus
- 5 October 2026
- Published by Springer Nature in BMC Endocrine Disorders
Open AccessSGLT2 inhibitor use and DEXA-derived bone health in type 2 diabetes mellitus
- Open Access
- 28 September 2026
- Published by Wiley in Journal of Diabetes
- Vol. 18 (10) , e70274
Glycated Albumin‐Guided Therapy: Biomarker Utility or Earlier Treatment Intensification?
- 28 September 2026
- Published by Wiley in Journal of Diabetes
- Vol. 18 (10) , e70274
Open AccessGlycated Albumin‐Guided Therapy: Biomarker Utility or Earlier Treatment Intensification?
- Open Access
- 4 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1995
Association Between the Triglyceride-to-HDL Cholesterol Ratio and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Real-World Retrospective Study
Background and Objectives: The triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) is a simple lipid index associated with insulin resistance and atherogenic dyslipidemia. Previous evidence has supported the TG/HDL-C ratio as a simple surrogate marker of insulin resistance and an adverse metabolic profile. However, its relationship with glycemic control in real-world patients with type 2 diabetes mellitus (T2DM) remains uncertain. This study evaluated the association between the TG/HDL-C ratio and poor glycemic control in patients with T2DM. Materials and Methods: This retrospective observational study included patients with T2DM followed in outpatient clinics. Poor glycemic control was defined as glycated hemoglobin A1c (HbA1c) ≥ 7%. The association between the TG/HDL-C ratio and glycemic control was assessed using group comparisons, Spearman correlation, tertile analysis, and multivariable logistic regression adjusted for age, sex, LDL-C, total cholesterol, insulin use, statin use, and fenofibrate use. Receiver operating characteristic (ROC) analysis was used to evaluate the discriminatory performance of the TG/HDL-C ratio for identifying poor glycemic control. A sensitivity analysis was performed after excluding patients receiving fenofibrate. Results: A total of 1001 patients with T2DM were included, of whom 568 (56.7%) had poor glycemic control. The mean age was 60.9 ± 11.4 years, and 57.1% of participants were women. The poor- and adequate-glycemic-control groups were comparable with respect to age and sex. The TG/HDL-C ratio was higher in patients with HbA1c ≥7% than in those with HbA1c < 7% [3.35 (2.35–5.00) vs. 2.74 (1.87–3.82), p < 0.001] and increased progressively across tertiles. In multivariable analysis, the TG/HDL-C ratio remained associated with poor glycemic control after adjustment for available covariates (OR: 1.201, 95% CI: 1.125–1.282, p < 0.001). The association remained significant after excluding fenofibrate users. ROC analysis showed modest discrimination (AUC: 0.601, 95% CI: 0.566–0.636). Conclusions: The TG/HDL-C ratio was associated with poor glycemic control in patients with T2DM, showing a graded association across tertiles. However, its standalone discriminatory performance is modest. Given its modest discriminatory performance, the TG/HDL-C ratio should not be considered a standalone diagnostic or predictive tool for poor glycemic control; rather, it may serve as an accessible adjunctive metabolic marker associated with an adverse glycemic and lipid profile.
- 4 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1995
Open AccessAssociation Between the Triglyceride-to-HDL Cholesterol Ratio and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Real-World Retrospective Study
Background and Objectives: The triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) is a simple lipid index associated with insulin resistance and atherogenic dyslipidemia. Previous evidence has supported the TG/HDL-C ratio as a simple surrogate marker of insulin resistance and an adverse metabolic profile. However, its relationship with glycemic control in real-world patients with type 2 diabetes mellitus (T2DM) remains uncertain. This study evaluated the association between the TG/HDL-C ratio and poor glycemic control in patients with T2DM. Materials and Methods: This retrospective observational study included patients with T2DM followed in outpatient clinics. Poor glycemic control was defined as glycated hemoglobin A1c (HbA1c) ≥ 7%. The association between the TG/HDL-C ratio and glycemic control was assessed using group comparisons, Spearman correlation, tertile analysis, and multivariable logistic regression adjusted for age, sex, LDL-C, total cholesterol, insulin use, statin use, and fenofibrate use. Receiver operating characteristic (ROC) analysis was used to evaluate the discriminatory performance of the TG/HDL-C ratio for identifying poor glycemic control. A sensitivity analysis was performed after excluding patients receiving fenofibrate. Results: A total of 1001 patients with T2DM were included, of whom 568 (56.7%) had poor glycemic control. The mean age was 60.9 ± 11.4 years, and 57.1% of participants were women. The poor- and adequate-glycemic-control groups were comparable with respect to age and sex. The TG/HDL-C ratio was higher in patients with HbA1c ≥7% than in those with HbA1c < 7% [3.35 (2.35–5.00) vs. 2.74 (1.87–3.82), p < 0.001] and increased progressively across tertiles. In multivariable analysis, the TG/HDL-C ratio remained associated with poor glycemic control after adjustment for available covariates (OR: 1.201, 95% CI: 1.125–1.282, p < 0.001). The association remained significant after excluding fenofibrate users. ROC analysis showed modest discrimination (AUC: 0.601, 95% CI: 0.566–0.636). Conclusions: The TG/HDL-C ratio was associated with poor glycemic control in patients with T2DM, showing a graded association across tertiles. However, its standalone discriminatory performance is modest. Given its modest discriminatory performance, the TG/HDL-C ratio should not be considered a standalone diagnostic or predictive tool for poor glycemic control; rather, it may serve as an accessible adjunctive metabolic marker associated with an adverse glycemic and lipid profile.
- Open Access
- 3 July 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Prevalence of food addiction and its association with ghrelin and metabolic parameters in patients with type 1 diabetes mellitus: a cross-sectional study
This study aimed to determine the prevalence of food addiction (FA) in adults with type 1 diabetes mellitus (T1DM) and examine its associations with serum ghrelin levels and metabolic control parameters. The study included 160 patients with a median age of 32.0 years (range: 19.0-60.0), of whom 51.3% (n = 82) were female. After recording anthropometric measurements, sociodemographic data, medical histories, and detailed physical examinations were obtained. Following an 8-hour fasting period, venous blood samples were collected to measure serum ghrelin levels and biochemical parameters. Serum ghrelin levels were assessed using the ELISA method. FA was evaluated using the modified Yale Food Addiction Scale 2.0 (mYFAS 2.0). FA prevalence was 25.6% (n = 41). The FA group had higher median BMI (p = 0.047), while monthly income, diabetes duration, and insulin pump use were lower (p = 0.025, p = 0.009, and p = 0.046, respectively). Age, gender, education, and metabolic control indicators (HbA1c, lipids) were similar between groups. Serum ghrelin levels did not differ based on FA status. However, ghrelin showed modest negative correlations with BMI (r=-0.171; p = 0.030), waist circumference (r=-0.256; p = 0.001), and triglycerides (r=-0.168; p = 0.033). Our findings indicate that the prevalence of FA is observed at considerable rates among patients with T1DM. Although no significant differences were observed in metabolic control parameters between patients with and without FA, the FA group exhibited a modestly higher BMI, suggesting a potential association between addiction-like eating behavior and adiposity in adults with T1DM. Not applicable.
- 3 July 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Open AccessPrevalence of food addiction and its association with ghrelin and metabolic parameters in patients with type 1 diabetes mellitus: a cross-sectional study
This study aimed to determine the prevalence of food addiction (FA) in adults with type 1 diabetes mellitus (T1DM) and examine its associations with serum ghrelin levels and metabolic control parameters. The study included 160 patients with a median age of 32.0 years (range: 19.0-60.0), of whom 51.3% (n = 82) were female. After recording anthropometric measurements, sociodemographic data, medical histories, and detailed physical examinations were obtained. Following an 8-hour fasting period, venous blood samples were collected to measure serum ghrelin levels and biochemical parameters. Serum ghrelin levels were assessed using the ELISA method. FA was evaluated using the modified Yale Food Addiction Scale 2.0 (mYFAS 2.0). FA prevalence was 25.6% (n = 41). The FA group had higher median BMI (p = 0.047), while monthly income, diabetes duration, and insulin pump use were lower (p = 0.025, p = 0.009, and p = 0.046, respectively). Age, gender, education, and metabolic control indicators (HbA1c, lipids) were similar between groups. Serum ghrelin levels did not differ based on FA status. However, ghrelin showed modest negative correlations with BMI (r=-0.171; p = 0.030), waist circumference (r=-0.256; p = 0.001), and triglycerides (r=-0.168; p = 0.033). Our findings indicate that the prevalence of FA is observed at considerable rates among patients with T1DM. Although no significant differences were observed in metabolic control parameters between patients with and without FA, the FA group exhibited a modestly higher BMI, suggesting a potential association between addiction-like eating behavior and adiposity in adults with T1DM. Not applicable.
- 25 June 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (3) , 539-546
Influenza and pneumococcal vaccination uptake, knowledge, and perceived necessity in adults with chronic diseases: a cross-sectional study
Aims: Influenza and pneumococcal infections cause substantial morbidity and mortality among adults with chronic diseases; however, vaccination coverage remains suboptimal despite strong international recommendations. This study aimed to evaluate influenza and pneumococcal vaccination uptake, knowledge, attitudes, perceived necessity, and barriers among adults with chronic diseases.Methods: This descriptive cross-sectional study included adults (≥18 years) with at least one chronic disease attending an internal medicine outpatient clinic. Data were collected using a structured 11-item questionnaire assessing vaccination status, knowledge, physician recommendations, perceived necessity, and barriers. Associations were examined using Chi-square tests and Cramer’s V. Results: Among 200 participants, 49.00% had ever received an influenza vaccine and 20.50% were vaccinated in the previous year, while pneumococcal vaccination uptake was 14.60%. Awareness that influenza vaccination should be administered annually was reported by 30.50%, and 55.10% were aware of the pneumococcal vaccine. The most common barriers were lack of physician recommendation (57.90%), insufficient information (45.10%), and fear of adverse effects (41.40%). Knowledge of annual influenza vaccination was significantly associated with prior influenza vaccination (p
- 25 June 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (3) , 539-546
Influenza and pneumococcal vaccination uptake, knowledge, and perceived necessity in adults with chronic diseases: a cross-sectional study
Aims: Influenza and pneumococcal infections cause substantial morbidity and mortality among adults with chronic diseases; however, vaccination coverage remains suboptimal despite strong international recommendations. This study aimed to evaluate influenza and pneumococcal vaccination uptake, knowledge, attitudes, perceived necessity, and barriers among adults with chronic diseases.Methods: This descriptive cross-sectional study included adults (≥18 years) with at least one chronic disease attending an internal medicine outpatient clinic. Data were collected using a structured 11-item questionnaire assessing vaccination status, knowledge, physician recommendations, perceived necessity, and barriers. Associations were examined using Chi-square tests and Cramer’s V. Results: Among 200 participants, 49.00% had ever received an influenza vaccine and 20.50% were vaccinated in the previous year, while pneumococcal vaccination uptake was 14.60%. Awareness that influenza vaccination should be administered annually was reported by 30.50%, and 55.10% were aware of the pneumococcal vaccine. The most common barriers were lack of physician recommendation (57.90%), insufficient information (45.10%), and fear of adverse effects (41.40%). Knowledge of annual influenza vaccination was significantly associated with prior influenza vaccination (p
- Open Access
- 15 April 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (8) , 1041
Development and Internal Validation of the Palliative Metabolic Risk Score (PMRS) for Predicting Critical Outcome in Palliative Inpatients
Background/Objectives: In-hospital critical outcome among palliative inpatients remains high, often driven by acute physiological instability rather than chronic comorbidities. Although diabetes mellitus (DM) is common in this population, its independent impact on critical outcome is unclear. This study aimed to determine whether acute metabolic and inflammatory markers—specifically glucose, C-reactive protein (CRP), albumin, and oxygen requirement—better predict short-term outcomes, defined as in-hospital critical outcome or ICU transfer during the same hospitalization period, than DM status alone. Methods: This retrospective study included 200 palliative inpatients admitted to the Internal Medicine Clinic of Kestel State Hospital, Bursa, Turkey, between January 2024 and January 2025. Demographic, clinical, and laboratory data were obtained from electronic records. The primary outcome was in-hospital critical outcome or ICU transfer (“critical outcome”). Logistic regression and receiver-operating characteristic (ROC) analyses identified independent predictors. The study was approved by the Bursa Yüksek İhtisas Training and Research Hospital Ethics Committee (ethics approval: protocol code 2024-TBEK 2025/05-12). Results: The mean age was 77.7 ± 12.3 years, and 47% were male. DM was present in 30.5% but did not independently predict critical outcome (p = 0.904). In contrast, oxygen requirement (OR = 4.08, p = 0.002), mean glucose (OR = 1.01, p = 0.001), and cancer (OR = 3.28, p = 0.016) were significant predictors. ROC analysis identified CRP > 64.1 mg/L and albumin < 25 g/L as optimal thresholds, and these two markers formed the basis of the low-, intermediate-, and high-risk stratification, with critical-outcome rates of 39.0%, 45.1%, and 85.4% (p < 0.001). Conclusions: Acute metabolic and inflammatory disturbances—particularly hyperglycemia, elevated CRP, hypoalbuminemia, and oxygen requirement—are stronger prognostic indicators than DM. A simple bedside model incorporating these parameters may improve prognostic accuracy and communication in palliative care.
- 15 April 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (8) , 1041
Open AccessDevelopment and Internal Validation of the Palliative Metabolic Risk Score (PMRS) for Predicting Critical Outcome in Palliative Inpatients
Background/Objectives: In-hospital critical outcome among palliative inpatients remains high, often driven by acute physiological instability rather than chronic comorbidities. Although diabetes mellitus (DM) is common in this population, its independent impact on critical outcome is unclear. This study aimed to determine whether acute metabolic and inflammatory markers—specifically glucose, C-reactive protein (CRP), albumin, and oxygen requirement—better predict short-term outcomes, defined as in-hospital critical outcome or ICU transfer during the same hospitalization period, than DM status alone. Methods: This retrospective study included 200 palliative inpatients admitted to the Internal Medicine Clinic of Kestel State Hospital, Bursa, Turkey, between January 2024 and January 2025. Demographic, clinical, and laboratory data were obtained from electronic records. The primary outcome was in-hospital critical outcome or ICU transfer (“critical outcome”). Logistic regression and receiver-operating characteristic (ROC) analyses identified independent predictors. The study was approved by the Bursa Yüksek İhtisas Training and Research Hospital Ethics Committee (ethics approval: protocol code 2024-TBEK 2025/05-12). Results: The mean age was 77.7 ± 12.3 years, and 47% were male. DM was present in 30.5% but did not independently predict critical outcome (p = 0.904). In contrast, oxygen requirement (OR = 4.08, p = 0.002), mean glucose (OR = 1.01, p = 0.001), and cancer (OR = 3.28, p = 0.016) were significant predictors. ROC analysis identified CRP > 64.1 mg/L and albumin < 25 g/L as optimal thresholds, and these two markers formed the basis of the low-, intermediate-, and high-risk stratification, with critical-outcome rates of 39.0%, 45.1%, and 85.4% (p < 0.001). Conclusions: Acute metabolic and inflammatory disturbances—particularly hyperglycemia, elevated CRP, hypoalbuminemia, and oxygen requirement—are stronger prognostic indicators than DM. A simple bedside model incorporating these parameters may improve prognostic accuracy and communication in palliative care.
- Open Access
- 27 March 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 32 (2) , 227-234
Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?
Objective: The use of medium and low-dose inhaled corticosteroids (ICS) did not increase the risk of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD). The goal is to look at the risk of osteoporosis that comes with Budesonide and Fluticasone when choosing ICS for people with COPD, since this group of people is more likely to get osteoporosis. Methods: Patients with Stage E COPD who were on ICS and came to a tertiary healthcare facility between January 2024 and January 2025 were included. There were three groups in the trial: people with COPD who were taking inhaled budesonide, those who were on fluticasone, and a control group. Results: The study comprised 122 participants: 16 COPD patients utilizing inhaled fluticasone, 16 COPD patients utilizing inhaled budesonide, and 90 individuals in the control group. The mean age of the study participants was 72.79 years; the mean age of the fluticasone group was 74.69 years, the mean age of the budesonide group was 73.19 years, and the mean age of the control group was 72.38 years. The groups exhibit no significant difference for osteoporosis (p>0.05). No significant difference was seen between the groups for the duration and intensity of ICS use (p>0.05). Conclusion: In individuals with COPD, the administration of budesonide and fluticasone as inhaled corticosteroid options has not elevated the risk of osteoporosis.
- 27 March 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 32 (2) , 227-234
Open AccessConsideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?
Objective: The use of medium and low-dose inhaled corticosteroids (ICS) did not increase the risk of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD). The goal is to look at the risk of osteoporosis that comes with Budesonide and Fluticasone when choosing ICS for people with COPD, since this group of people is more likely to get osteoporosis. Methods: Patients with Stage E COPD who were on ICS and came to a tertiary healthcare facility between January 2024 and January 2025 were included. There were three groups in the trial: people with COPD who were taking inhaled budesonide, those who were on fluticasone, and a control group. Results: The study comprised 122 participants: 16 COPD patients utilizing inhaled fluticasone, 16 COPD patients utilizing inhaled budesonide, and 90 individuals in the control group. The mean age of the study participants was 72.79 years; the mean age of the fluticasone group was 74.69 years, the mean age of the budesonide group was 73.19 years, and the mean age of the control group was 72.38 years. The groups exhibit no significant difference for osteoporosis (p>0.05). No significant difference was seen between the groups for the duration and intensity of ICS use (p>0.05). Conclusion: In individuals with COPD, the administration of budesonide and fluticasone as inhaled corticosteroid options has not elevated the risk of osteoporosis.
- Open Access
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47360
Are lipid-lowering therapies used according to the guidelines?: A real-world retrospective study of 1001 patients with type 2 diabetes
Type 2 diabetes mellitus (T2DM) is frequently complicated by dyslipidemia, which increases the cardiovascular risk. Although guidelines strongly recommend lipid-lowering therapy, real-world treatment thresholds and adherence remain inconsistent in the literature. This retrospective observational study included 1001 patients with T2DM who attended outpatient clinics between March 2024 and March 2025. Demographic characteristics, metabolic parameters, and medication use (statins, fibrates, insulin, and neuropathy drugs) were retrieved from the hospital records. Group comparisons were performed using parametric and nonparametric tests, and multivariate logistic regression was used to identify the independent predictors of drug use. The mean age of the cohort was 60.9 ± 11.4 years, and 57.1% of the patients were female. The mean HbA1c was 7.47 ± 1.56%, low-density lipoprotein (LDL) was 110.7 ± 42.8 mg/dL, high-density lipoprotein was 49.6 ± 14.0 mg/dL, and triglycerides (TG) were 172.7 ± 100.1 mg/dL. Statin users had higher LDL and high-density lipoprotein levels but lower TG levels than nonusers. Fenofibrate users exhibited markedly higher TG levels. Insulin therapy was associated with poorer glycemic control but did not significantly affect the lipid parameters. In logistic regression, statin use was independently predicted by higher HbA1c and LDL levels, whereas fibrate use was predicted by elevated TG levels. Age was the only independent predictor of neuropathic drug use. In this real-world T2DM cohort, the initiation of statins and fibrates did not align with guideline-based thresholds. Statins were prescribed at higher LDL levels, whereas fibrates were reserved for patients with severely elevated TG levels. These findings highlight the persistent gap between guidelines and clinical practice and emphasize the need for strategies to improve lipid management in secondary-care settings.
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47360
Open AccessAre lipid-lowering therapies used according to the guidelines?: A real-world retrospective study of 1001 patients with type 2 diabetes
Type 2 diabetes mellitus (T2DM) is frequently complicated by dyslipidemia, which increases the cardiovascular risk. Although guidelines strongly recommend lipid-lowering therapy, real-world treatment thresholds and adherence remain inconsistent in the literature. This retrospective observational study included 1001 patients with T2DM who attended outpatient clinics between March 2024 and March 2025. Demographic characteristics, metabolic parameters, and medication use (statins, fibrates, insulin, and neuropathy drugs) were retrieved from the hospital records. Group comparisons were performed using parametric and nonparametric tests, and multivariate logistic regression was used to identify the independent predictors of drug use. The mean age of the cohort was 60.9 ± 11.4 years, and 57.1% of the patients were female. The mean HbA1c was 7.47 ± 1.56%, low-density lipoprotein (LDL) was 110.7 ± 42.8 mg/dL, high-density lipoprotein was 49.6 ± 14.0 mg/dL, and triglycerides (TG) were 172.7 ± 100.1 mg/dL. Statin users had higher LDL and high-density lipoprotein levels but lower TG levels than nonusers. Fenofibrate users exhibited markedly higher TG levels. Insulin therapy was associated with poorer glycemic control but did not significantly affect the lipid parameters. In logistic regression, statin use was independently predicted by higher HbA1c and LDL levels, whereas fibrate use was predicted by elevated TG levels. Age was the only independent predictor of neuropathic drug use. In this real-world T2DM cohort, the initiation of statins and fibrates did not align with guideline-based thresholds. Statins were prescribed at higher LDL levels, whereas fibrates were reserved for patients with severely elevated TG levels. These findings highlight the persistent gap between guidelines and clinical practice and emphasize the need for strategies to improve lipid management in secondary-care settings.
- RetractedOpen Access
- 1 December 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2590865
High-frequency hearing loss in chronic kidney disease: a frequency-specific analysis across renal function stages
Chronic kidney disease (CKD) has been associated with a wide range of neurological complications, yet the onset and pattern of hearing loss, particularly at high frequencies, remain insufficiently characterized. This study aimed to evaluate hearing function across different stages of renal impairment with a focus on frequency-specific thresholds. A total of 97 participants were retrospectively assessed and divided into three groups: preserved estimated glomerular filtration rate (eGFR) (n = 32), CKD without hemodialysis (n = 32), and patients undergoing hemodialysis (n = 33). Pure-tone audiometry was performed to assess both conventional and high-frequency hearing thresholds. Comparative analyses using Kruskal-Wallis and Mann-Whitney U-tests were conducted. Patients with CKD, even those not receiving hemodialysis (HD), exhibited significantly worse high-frequency hearing thresholds compared to controls (p < 0.05). The greatest degree of hearing impairment was observed in the HD group. Receiver operating characteristic analysis indicated that high-frequency audiometry moderately predicted CKD status, with area under the curve values exceeding 0.70. Logistic regression further demonstrated that age and CKD status were significant predictors of hearing loss (p < 0.01) These findings provide novel frequency-specific evidence that compared with controls, patients with non HD CKD already demonstrate poorer high-frequency thresholds, suggesting possible early involvement even prior to the initiation of HD. The results underscore the importance of routine high-frequency audiological screening for CKD patients, as early detection may help to prevent or mitigate further deterioration in auditory function. This study is among the first to demonstrate frequency-specific differences in hearing loss across distinct renal function groups.
- 1 December 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2590865
RetractedOpen AccessHigh-frequency hearing loss in chronic kidney disease: a frequency-specific analysis across renal function stages
Chronic kidney disease (CKD) has been associated with a wide range of neurological complications, yet the onset and pattern of hearing loss, particularly at high frequencies, remain insufficiently characterized. This study aimed to evaluate hearing function across different stages of renal impairment with a focus on frequency-specific thresholds. A total of 97 participants were retrospectively assessed and divided into three groups: preserved estimated glomerular filtration rate (eGFR) (n = 32), CKD without hemodialysis (n = 32), and patients undergoing hemodialysis (n = 33). Pure-tone audiometry was performed to assess both conventional and high-frequency hearing thresholds. Comparative analyses using Kruskal-Wallis and Mann-Whitney U-tests were conducted. Patients with CKD, even those not receiving hemodialysis (HD), exhibited significantly worse high-frequency hearing thresholds compared to controls (p < 0.05). The greatest degree of hearing impairment was observed in the HD group. Receiver operating characteristic analysis indicated that high-frequency audiometry moderately predicted CKD status, with area under the curve values exceeding 0.70. Logistic regression further demonstrated that age and CKD status were significant predictors of hearing loss (p < 0.01) These findings provide novel frequency-specific evidence that compared with controls, patients with non HD CKD already demonstrate poorer high-frequency thresholds, suggesting possible early involvement even prior to the initiation of HD. The results underscore the importance of routine high-frequency audiological screening for CKD patients, as early detection may help to prevent or mitigate further deterioration in auditory function. This study is among the first to demonstrate frequency-specific differences in hearing loss across distinct renal function groups.
- 3 October 2025
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 23 (8) , 381-387
The Significance of Mean Platelet Volume in Assessing Amputation Risk in Patients with Diabetic Foot Ulcers: A Cohort Study
Objective: Diabetic foot ulcer is a condition associated with type 2 diabetes mellitus (T2DM). This study aims to examine the influence of mean platelet volume (MPV) on predicting amputation decisions in patients with diabetic foot ulcers. Methods: Patients with diabetic foot ulcers who presented to the tertiary healthcare facility from June 2023 to June 2024 were included. The first group comprises individuals who opted for amputation, whereas the second group includes patients without indications for amputation. Results: The mean age of patients with diabetic foot ulcers is 62.68 years, and the mean glycated hemoglobin A1c level is 9.62%. The initial group comprises 61 patients who opted for amputation, whereas the subsequent group includes 56 individuals who lacked an indication for amputation. The initial group exhibits markedly elevated values for MPV, total cholesterol, and low-density lipoprotein (LDL) ( P = 0.001, P = 0.004, P = 0.020). Logistic regression research indicates that elevated levels of LDL and MPV substantially heighten the chance of amputation. The receiver operating characteristic curve study established the MPV cutoff value for amputation prediction at 11.2. The sensitivity and specificity of this value in predicting amputation were [ β = 0.01, OR (odds ratio) = 1.01, 95% confidence interval (CI): 1.00–1.03, P = 0.006] for LDL and ( β = 0.52, OR = 1.68, 95% CI: 1.18–2.39, P = 0.003) for MPV. Every unit increment in the MPV value corresponds to an approximate 68.8% elevation in the probability of amputation. Conclusion: In individuals with diabetic foot ulcers, MPV and LDL levels are independent variables affecting amputation and may function as predictors for amputation.
- 3 October 2025
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 23 (8) , 381-387
The Significance of Mean Platelet Volume in Assessing Amputation Risk in Patients with Diabetic Foot Ulcers: A Cohort Study
Objective: Diabetic foot ulcer is a condition associated with type 2 diabetes mellitus (T2DM). This study aims to examine the influence of mean platelet volume (MPV) on predicting amputation decisions in patients with diabetic foot ulcers. Methods: Patients with diabetic foot ulcers who presented to the tertiary healthcare facility from June 2023 to June 2024 were included. The first group comprises individuals who opted for amputation, whereas the second group includes patients without indications for amputation. Results: The mean age of patients with diabetic foot ulcers is 62.68 years, and the mean glycated hemoglobin A1c level is 9.62%. The initial group comprises 61 patients who opted for amputation, whereas the subsequent group includes 56 individuals who lacked an indication for amputation. The initial group exhibits markedly elevated values for MPV, total cholesterol, and low-density lipoprotein (LDL) ( P = 0.001, P = 0.004, P = 0.020). Logistic regression research indicates that elevated levels of LDL and MPV substantially heighten the chance of amputation. The receiver operating characteristic curve study established the MPV cutoff value for amputation prediction at 11.2. The sensitivity and specificity of this value in predicting amputation were [ β = 0.01, OR (odds ratio) = 1.01, 95% confidence interval (CI): 1.00–1.03, P = 0.006] for LDL and ( β = 0.52, OR = 1.68, 95% CI: 1.18–2.39, P = 0.003) for MPV. Every unit increment in the MPV value corresponds to an approximate 68.8% elevation in the probability of amputation. Conclusion: In individuals with diabetic foot ulcers, MPV and LDL levels are independent variables affecting amputation and may function as predictors for amputation.